Mankind’s Deal With Ex-J&J Exec Paul Stoffels’ Firm Armed Cell Gives CAR-T Toehold
Mankind Pharma is paying €48m to acquire a 70% stake in Armed Cell, the Paul Stoffels-chaired CAR-T start-up that a day earlier bought Lakefront’s preclinical pipeline, giving the Indian major its first global innovation toehold.
Scrip - October 15, 2026

Lakefront Sells Off Preclinical CAR-T Assets To Focus On Autoimmune Programs
Deal Snapshot: The Belgian biotech, formerly Galapagos, took control of the CAR-Ts in mid-2022 but is now selling them to Armed Cell Therapeutics, the result of a wind-down in cell therapy activity announced in October 2025.
Scrip - October 15, 2026

Finance Watch: Venture Capital Investors Raise $6.2bn Across Five New Funds
Private Company Edition: OrbiMed raised $1.9bn for US and European investments and more than $1bn for an Asia-focused fund, while Forbion raised €2.3bn ($2.6bn) for its venture and opportunities funds, and TCGX closed a $600m fund for investment in Asia.
Scrip - October 15, 2026

Osivax Looks To Combination Potential After Flu Vaccine Misses Endpoint
Osivax’s nucleoprotein-targeting seasonal flu vaccine failed to show 50% vaccine efficacy in a Phase IIb study, but the French firm plans to test OVX836 in a dual-antigen approach.
Scrip - October 15, 2026

Biopharma VC Investment Slumps In Q3, But 2026 Still On Track For Growth
Venture capital investment in drug developers fell from $10.17bn in the second quarter to $6.44bn in the third, but year-to-date fundraising is just $1.1bn away from the full-year 2025 total.
Scrip - October 15, 2026

Ultragenyx In The Money As PRV Income Tops $400m
The company has sold two rare pediatric disease priority review vouchers in the space of a week.
Scrip - October 15, 2026

Genfleet/Verastem Eye World-First Phase III Trials For KRAS G12D Inhibitor In CRC
Partners separately announce strong Phase I data and Phase III plans for GFH375 (VS-7375), an oral KRAS G12D (ON/OFF) inhibitor, for colorectal cancer in and outside of China.
Scrip - October 15, 2026

OMass Aims To Be ‘Britain’s Big Biotech’
As the Oxford-headquartered firm raises $310m, CEO Ros Deegan tells Scrip about its hopes to produce a broad pipeline across endocrinology and immunology.
Scrip - October 15, 2026

Stryker’s $400M Funding In CMR Surgical ‘Gives It Another Potential Growth Vertical,’ Analysts Say
Stryker’s $400m CMR Surgical stake, with exclusive US sales rights and a buyout option, opens a soft-tissue robotics vertical aimed at outpatient centers.
Medtech Insight - October 15, 2026

Labcorp To Pay Up To $872M For BioReference Health Assets, Including 4Kscore Prostate Test
Labcorp will pay $722m in cash at closing, plus up to $150m tied to revenue, for BioReference Health’s labs, more than 80 patient service centers and the FDA-approved prostate cancer test. Parent company OPKO says the sale lets it focus on its biopharmaceutical business.
Medtech Insight - October 15, 2026

Execs On The Move: October 5–9, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - October 15, 2026

US FDA Wants Advisory Committee Members, But Not Voting Consumer Reps
A nationwide nomination push is a sharp break from former Commissioner Martin Makary’s aversion to advisory committees, even as charter renewals have quietly moved most drug and biologic consumer representative seats to nonvoting status.
HBW Insight - October 16, 2026

Murphy Steps Down As FDA’s OGD Director Amid ‘Political Pressure,’ Admin Burden
Iilun Murphy decided to step down as Office of Generic Drugs director for an associate director position, another senior leadership change under the Trump administration.
Generics Bulletin - October 15, 2026

Accord Builds On US Portfolio Dream With Filgrastim Biosimilar Launch
Accord’s goal of commercializing 20 US biosimilars by 2030 is a step closer with the latest biosimilar launch of Filkri (filgrastim-laha). However, the firm enters a mature and established filgrastim biosimilars market.
Generics Bulletin - October 15, 2026

Alvotech And Advanz Are First To Take Aim At Eylea HD
Partners Alvotech and Advanz Pharma have claimed pole position globally with their filing for a high-dose aflibercept 8mg biosimilar in Europe, based on Regeneron’s Eylea HD.
Generics Bulletin - October 15, 2026

Beyond The Base Case: Why Biosimilar Companies Need Two Forecasting Engines, Not One
Biosimilar bets are forecasts built on a forecast: estimate the originator's value at LOE a decade out, while the molecule is still gaining indications and facing new competition, then project your own launch on top. The industry's instinct is one tidy framework. The two problems are not the same.
In Vivo - October 15, 2026

Picking The Wrong Biosimilar Costs A Decade, Not A Quarter
Biosimilar developers must value someone else's molecule a decade out, then forecast their own share of it. Currently the industry uses one instrument for both jobs. When the case is tested against the record: the diagnosis holds, the prescription is untested.
In Vivo - October 15, 2026